The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7.
A20 possesses both deubiquitinase (DUB) and ubiquitin E3 ligase activities that are required for termination of Toll-like receptor (TLR) signaling leading to NF-kappaB activation and for blockage of tumor necrosis factor (TNF)-induced cytotoxicity and apoptosis. A20 is induced by the Epstein-Barr virus (EBV) oncoprotein LMP1. However, its dual ubiquitin-editing activities have not been investigated in the context of either EBV infection or IRF7 responses. Both A20 and IRF7 have oncogenic properties. We have recently shown that LMP1 activates IRF7 through K63-linked ubiquitination which requires RIP1 and TRAF6, but how this ubiquitination event is regulated has not been studied. Here, we show that A20 negatively regulates IRF7 transcriptional activity induced by LMP1. Deletion or mutation of A20 C-terminal zinc finger motifs had no effect on the inhibition of IRF7 activity, whereas DUB-deficient truncation or point mutation ablated the ability of A20 to inhibit IRF7. Correspondingly, the A20 N-terminal DUB domain, but not the C-terminal E3 ligase domain, interacts physically with IRF7. Transient expression of A20 reduced K63-linked ubiquitination of IRF7 in vivo, but an in vitro deubiquitination assay with purified constituents shows that IRF7 did not act as a substrate for A20 DUB activity. Moreover, A20 interacts with IRF7 endogenously in latently EBV-infected type 3 Raji cells, in which expression of both A20 and IRF7 is constitutively induced by the considerable level of endogenous LMP1. Knockdown of endogenous A20 in Raji cells by expression of A20 short hairpin RNA (shRNA) vectors increases endogenous IRF7 activity and ubiquitination, as well as the protein level of LMP1, a target of IRF7. Thus, A20 negatively regulates LMP1-stimulated IRF7 ubiquitination and activity in EBV latency, and its DUB activity is indispensable for this function. Finally, we discussed the regulation and function of IRFs in EBV latency.
Ning
Shunbin
S
Division of Hematology/Oncology, Department of Medicine, Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA. sning@med.miami.edu
Pagano
Joseph S
JS
D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins; D020031:Epstein-Barr Virus Infections / Q000235:genetics / Q000378:metabolism*; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D050839:Interferon Regulatory Factor-7 / Q000235:genetics / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3; D054875:Ubiquitination; D014763:Viral Matrix Proteins / Q000235:genetics / Q000378:metabolism*
D004268:DNA-Binding Proteins; C037662:EBV-associated membrane antigen, Epstein-Barr virus; C494234:IRF7 protein, human; D050839:Interferon Regulatory Factor-7; D047908:Intracellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D014763:Viral Matrix Proteins; C076529:TNFAIP3 protein, human; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15989-94
16236719
Mol Cell Biol. 2004 Jun;24(12):5089-93
15169876
Pharmacol Ther. 2009 Nov;124(2):219-34
19615405
Annu Rev Biochem. 2009;78:399-434
19489725
Immunol Lett. 2009 Jan 29;122(1):1-11
19059436
J Virol. 2005 Feb;79(3):1724-33
15650197
Immunity. 2006 Sep;25(3):373-81
16979569
PLoS One. 2009;4(5):e5500
19430534
J Biol Chem. 2006 Jan 27;281(4):2095-103
16306043
Cell. 2009 Aug 7;138(3):576-91
19631370
Nat Immunol. 2004 Oct;5(10):1052-60
15334086
Nat Rev Immunol. 2006 Sep;6(9):644-58
16932750
Mol Cell. 2009 Feb 13;33(3):275-86
19217402
PLoS One. 2009 Jun 18;4(6):e5955
19536331
Nat Rev Immunol. 2008 Jul;8(7):559-68
18575461
Oncogene. 2005 Mar 3;24(10):1711-7
15674340
Blood. 2009 Apr 2;113(14):3264-75
18952891
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6
14663138
EMBO J. 2009 Mar 4;28(5):513-22
19131965
Biochem J. 2005 Apr 1;387(Pt 1):47-55
15527421
J Virol. 2000 Feb;74(3):1061-8
10627515
J Gen Virol. 2008 Jan;89(Pt 1):1-47
18089727
Mol Cell Biol. 2008 Oct;28(20):6536-46
18710948
Virology. 1999 Nov 10;264(1):159-66
10544141
Mol Cell Biol. 2007 Nov;27(21):7451-61
17709380
Semin Cancer Biol. 2008 Dec;18(6):423-36
18948197
Mol Cell Biol. 1997 Feb;17(2):873-86
9001242
J Immunol. 2005 Feb 1;174(3):1507-12
15661910
BMC Biochem. 2007 Nov 22;8 Suppl 1:S8
18047745
Mol Cell Biol. 2007 Apr;27(8):2910-8
17296724
J Virol. 2008 Jul;82(13):6251-8
18417578
Nature. 2007 Jul 26;448(7152):501-5
17618271
Nat Rev Immunol. 2006 Nov;6(11):823-35
17063184
PLoS One. 2009 Aug 26;4(8):e6764
19707515
Mol Cell Biol. 1997 Oct;17(10):5748-57
9315633
Oncogene. 1997 Jun 19;14(24):2899-916
9205097
Semin Immunol. 2009 Aug;21(4):215-22
19539500
J Virol. 2008 Nov;82(21):10477-86
18715931
J Virol. 2008 Nov;82(21):10436-43
18753206
J Virol. 1996 Dec;70(12):8653-9
8970991
Blood. 2009 Sep 17;114(12):2467-75
19608751
Nat Rev Mol Cell Biol. 2009 Aug;10(8):550-63
19626045
Mol Cell Biol. 1999 Apr;19(4):3216-23
10082588
J Exp Med. 2003 Oct 6;198(7):1043-55
14517278
Nat Immunol. 2009 Nov;10(11):1200-7
19801985
Oncogene. 2006 Jan 12;25(2):288-97
16247482
J Biol Chem. 2005 Apr 1;280(13):12262-70
15664995
N Engl J Med. 2002 Jul 11;347(2):78-9
12110734
J Biomed Sci. 2003 Sep-Oct;10(5):490-504
12928589
Nature. 2004 Aug 5;430(7000):694-9
15258597
J Virol. 2009 May;83(9):4345-53
19244336
J Virol. 2005 Sep;79(18):11671-6
16140744
Science. 2007 Dec 7;318(5856):1628-32
17991829
J Virol. 2007 Sep;81(18):9748-58
17609264
J Biol Chem. 1992 Dec 5;267(34):24157-60
1332946
J Biol Chem. 1990 Sep 5;265(25):14705-8
2118515
J Virol. 2003 Sep;77(17):9359-68
12915551
J Immunol. 2007 Feb 15;178(4):2429-39
17277150
Nat Immunol. 2008 Mar;9(3):254-62
18246070
FEBS Lett. 2004 Oct 8;576(1-2):86-90
15474016
J Biol Chem. 2006 Apr 7;281(14):9163-9
16469740
J Exp Med. 2009 May 11;206(5):981-9
19380639
Essays Biochem. 2005;41:139-56
16250903
J Virol. 2001 Jan;75(1):341-50
11119603
Nat Immunol. 2009 Oct;10(10):1073-80
19701189
Nat Immunol. 2009 Oct;10(10):1065-72
19609254
Nat Rev Drug Discov. 2007 Dec;6(12):975-90
18049472
PLoS Pathog. 2008 Oct 03;4(10):e1000170
18833293
Nature. 2009 Mar 26;458(7237):430-7
19325622
Nat Rev Mol Cell Biol. 2009 Jun;10(6):398-409
19436320
Nat Rev Immunol. 2008 Jul;8(7):501-11
18535581
Mol Cell Biol. 2008 Aug;28(16):5027-42
18573890
FEBS Lett. 2009 May 19;583(10):1567-74
19379743
J Virol. 1997 Sep;71(9):6887-97
9261415